Transforming the Debridement Experience for Patients and Physicians
tl;dr
Kent Imaging partners with MDM Wound Ventures to improve wound debridement with NIRS imaging and EZDebride.
This collaboration enhances patient care, reduces costs, and minimizes pain, offering precise tissue viability assessments and efficient debridement.
The joint effort aims to promote advanced wound care technology, ensuring better patient outcomes and streamlined clinical processes.
Kent Imaging Joins Forces with MDM Wound Ventures
Kent Imaging, a leader in near-infrared spectroscopy (NIRS) imaging, has partnered with MDM Wound Ventures, the pioneers behind the sharp debridement instrument, EZDebride, to address common challenges during wound debridement in wound care settings. This synergistic collaboration will streamline patient care at the bedside, saving time and cost for the hospital or clinic, and reducing pain for the patient. The collaboration between the companies with respect to marketing, distribution and development will enhance clinical understanding and exposure of wound care products that are impacting the standard of care of debridement interventions.
Wound debridement may be implemented after careful clinical consideration, and the addition of nearly instantaneous tissue viability assessment imaging at the point-of-care allows providers to be more precise when it comes debriding the patient’s wound. Dr. Francis Derk (United States Navy and Marine Corps: CAPT) and MDM’s Chief Medical Officer has a fluid understanding of the treatment of chronic wounds, “A multi-modal approach targeting specific intervention goals is key to a patient's recovery,” he continues, “Addressing tissue oxygenation with objective data using SnapshotNIR is the addition that sharp debridement requires for efficient and successful patient outcomes.”
Read more about how Kent Imaging is transforming wound care.
SnapshotNIR is a NIRS device that measures oxyhemoglobin (oxy) and deoxyhemoglobin (deoxy) to calculate tissue oxygen saturation (StO2) in the tissue 2-3mm below the surface of the wound. Following wound debridement, clinicians should be observant of hemoglobin trends on SnapshotNIR. Upwards trending oxy and downwards trending deoxy can be indicative of an adequately debrided wound. Jeffrey Niezgoda, MD, Chief Medical Officer of Limb Preservation at Kent Imaging, has vast experience in advanced wound care including debridement techniques and technologies. He comments, “Having used a variety of debridement tools in the clinic, I can speak to the ease of use and effectiveness of EZDebride.”
Using SnapshotNIR to determine patient baseline StO2 pre-intervention, wound care providers will have the answer to an essential question regarding wounds: does the wound have enough oxygen to heal? Debriding the wound with EZDebride minimizes procedural pain while providing maximal benefit in promoting angio- and vasculo-genesis. To enhance clinical assessments, wound care providers can re-image with SnapshotNIR to monitor the change from baseline of hemoglobin and StO2. “It was an obvious collaboration to partner with MDM Wound Ventures, seeing how the impact of their instrument could be elevated with the microcirculatory vision of SnapshotNIR,” says Pierre Lemire, Chief Executive Officer of Kent Imaging.
Physicians can expect a debridement workflow that promotes timely diagnostics and objective, actionable data to complement clinical decision-making. Andrew Rader, DPM and owner of Indiana Foot and Ankle, has implemented SnapshotNIR and EZDebride successfully into his wound care arsenal. With over 30 years in the surgical and wound care industries, he is looking forward to the future stating, “The partnership between Kent Imaging and MDM signifies a pioneering collaboration that merges innovation and advanced wound care technology, promising enhanced patient outcomes and streamlined processes for physicians at the forefront of medical evolution.” With the combination of MDM’s EZDebride and Kent Imaging’s SnapshotNIR, wound debridement procedures can be clinically effective and patient-optimized supporting each company’s vision of improving patient outcomes.
About Kent Imaging
Located in Calgary, Alberta, Kent is a leading innovator in near-infrared tissue oxygenation imaging, which develops, manufactures, and markets medtech that supports real-time decision-making in wound care, vascular and surgical subspecialties. Kent holds multiple patents in oxygen imaging technology and provides advanced diagnostic imaging solutions to aid healthcare systems.
Related Content
